RSV in infants: A comprehensive guide from disease to treatment

RSV in infants: A comprehensive guide from disease to treatment

Family MedicineGeneral PracticePaediatricsInfectious DiseasesRespiratory Medicine
A badge with ribbon in color black Cat3B: 1 point | An analog clock in color black 1 Hour | A black calendar with white triangle in center that has a black exclamation point in the middle 10 Dec 2026 

Overview

About this course

Respiratory syncytial virus (RSV) is a common respiratory virus transmitted through respiratory droplets. While RSV infection causes mild cold-like symptoms for most adults, infants and at-risk individuals can develop serious respiratory symptoms such as bronchiolitis and pneumonia.

Current treatments for RSV in infants are supportive, and RSV management focuses primarily on prevention through immunisation. New and emerging options for RSV prevention such as vaccines and monoclonal antibodies are becoming available; they work by providing passive immunity to infants. Understanding the mechanism of RSV immunisation is crucial for grasping its protection characteristics, including duration and consistency of protection, as well as its potential benefits and limitations.

This e-learning module provides an overview of the various clinical presentations of RSV infection in infants, the burden of RSV in infants, and current strategies available for RSV prevention, plus their real-world evidence.

Learning outcomes

At the end of this learning module, participants should be able to:

  • Recognise the burden of RSV in infants
  • Understand RSV seasonality, transmission and pathogenesis
  • Identify the symptoms of RSV infection and its severity in infants
  • Differentiate various preventative strategies against RSV
  • Understand how monoclonal antibodies help to prevent RSV

Topics covered

  • Fundamentals of RSV
  • Clinical presentations of RSV infection in infants
  • RSV seasonality
  • Burden of RSV infection
  • Current measures in RSV prevention and treatment
  • Direct immunisation of infants with extended half-life monoclonal antibody nirsevimab to prevent RSV
  • Comparison of various preventive strategies against RSV infection
  • Real-world evidence for nirsevimab
  • Recommendations on RSV immunisation

CAT3B: 1 Point Available

  • Score at least 80% on the quiz.
  • A certificate can be downloaded upon successful completion of the quiz. Please use the information on the certificate to claim your CPD points.
Something went wrong.